Danaher Co. (NYSE:DHR) Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its position in shares of Danaher Co. (NYSE:DHR - Free Report) by 0.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,673,039 shares of the conglomerate's stock after selling 6,752 shares during the period. Danaher accounts for about 3.6% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings, making the stock its 8th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.23% of Danaher worth $419,247,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Heck Capital Advisors LLC bought a new stake in Danaher during the fourth quarter valued at $27,000. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the fourth quarter worth about $31,000. Golden State Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter worth approximately $31,000. Strategic Financial Concepts LLC purchased a new stake in Danaher in the fourth quarter valued at approximately $31,000. Finally, Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the third quarter valued at approximately $39,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company's stock.

Remove Ads

Danaher Stock Performance

NYSE:DHR traded up $0.60 during mid-day trading on Wednesday, reaching $202.22. The company's stock had a trading volume of 7,207,744 shares, compared to its average volume of 4,373,626. The firm's fifty day moving average price is $231.17 and its two-hundred day moving average price is $250.62. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market cap of $146.06 billion, a P/E ratio of 38.30, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the company posted $2.09 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.53%. Danaher's payout ratio is 20.45%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. Wells Fargo & Company dropped their price target on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. StockNews.com downgraded Danaher from a "buy" rating to a "hold" rating in a report on Saturday, December 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Finally, Citigroup dropped their price target on Danaher from $285.00 to $265.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.